References
1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: a
cancer journal for clinicians . Jan 2017;67(1):7-30.
doi:10.3322/caac.21387
2. Sattler M, Griffin JD. Mechanisms of transformation by the BCR/ABL
oncogene. International journal of hematology . Apr
2001;73(3):278-91. doi:10.1007/bf02981952
3. Roy L, Guilhot J, Martineau G, Larchee R, Guilhot F. Unexpected
occurrence of second malignancies in patients treated with interferon
followed by imatinib mesylate for chronic myelogenous leukemia.Leukemia . Sep 2005;19(9):1689-92. doi:10.1038/sj.leu.2403874
4. Sasaki K, Kantarjian HM, O’Brien S, et al. Incidence of second
malignancies in patients with chronic myeloid leukemia in the era of
tyrosine kinase inhibitors. International journal of hematology .
May 2019;109(5):545-552. doi:10.1007/s12185-019-02620-2
5. Krishnan B, Morgan GJ. Non-Hodgkin lymphoma secondary to cancer
chemotherapy. Cancer epidemiology, biomarkers & prevention : a
publication of the American Association for Cancer Research, cosponsored
by the American Society of Preventive Oncology . Mar 2007;16(3):377-80.
doi:10.1158/1055-9965.epi-06-1069
6. Pilot PR, Sablinska K, Owen S, Hatfield A. Epidemiological analysis
of second primary malignancies in more than 9500 patients treated with
imatinib. Leukemia . Jan 2006;20(1):148; author reply 149.
doi:10.1038/sj.leu.2404025
7. Verma D, Kantarjian H, Strom SS, et al. Malignancies occurring during
therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid
leukemia (CML) and other hematologic malignancies. Blood . Oct 20
2011;118(16):4353-8. doi:10.1182/blood-2011-06-362889
8. Shah BK, Ghimire KB. Second primary malignancies in chronic myeloid
leukemia. Indian journal of hematology & blood transfusion : an
official journal of Indian Society of Hematology and Blood Transfusion .
Dec 2014;30(4):236-40. doi:10.1007/s12288-013-0328-2
9. Gunnarsson N, Stenke L, Hoglund M, et al. Second malignancies
following treatment of chronic myeloid leukaemia in the tyrosine kinase
inhibitor era. British journal of haematology . Jun
2015;169(5):683-8. doi:10.1111/bjh.13346
10. Rodler E, Welborn J, Hatcher S, et al. Blastic mantle cell lymphoma
developing concurrently in a patient with chronic myelogenous leukemia
and a review of the literature. American journal of hematology .
Apr 2004;75(4):231-8. doi:10.1002/ajh.20025
11. Mihaylov G, Varbanova V, Stoeva V, Dikov T. Extranodal marginal zone
B-cell lymphoma arising in chronic myeloid leukaemia successfully
treated with tyrosine kinase inhibitor: a case report.Hippokratia . Jul-Sep 2016;20(3):241-243.
12. Takeyasu Y, Satake A, Azuma Y, et al. Tyrosine kinase inhibitor and
rituximab-CHOP treatment for concurrent chronic myeloid leukemia and
non-Hodgkin lymphoma: a case report. Clinical case reports . Dec
2017;5(12):2047-2050. doi:10.1002/ccr3.1253
13. Abuelgasim KA, Rehan H, Alsubaie M, et al. Coexistence of chronic
myeloid leukemia and diffuse large B-cell lymphoma with antecedent
chronic lymphocytic leukemia: a case report and review of the
literature. Journal of medical case reports . Mar 11
2018;12(1):64. doi:10.1186/s13256-018-1612-4
14. Fujiwara SI, Shirato Y, Ikeda T, et al. Successful treatment of
follicular lymphoma with second-generation tyrosine kinase inhibitors
administered for coexisting chronic myeloid leukemia.International journal of hematology . Jun 2018;107(6):712-715.
doi:10.1007/s12185-017-2378-y
15. Gajendra S, Sharma A, Sharma R, Gupta SK, Sood N, Sachdev R. Hodgkin
Lymphoma in a Case of Chronic Myeloid Leukemia Treated with Tyrosine
Kinase Inhibitors. Turk patoloji dergisi . 2019;35(1):74-78.
Hodgkin Lymphoma in a Case of Chronic Myeloid Leukemia Treated with
Tyrosine Kinase Inhibitors. doi:10.5146/tjpath.2016.01368
16. Cai Z, Liu S, Zi J, Ma J, Ge Z. A case of primary gastric diffuse
large B-cell lymphoma occurring in chronic myeloid leukemia.OncoTargets and therapy . 2019;12:5917-5923.
doi:10.2147/ott.s212838
17. Dominguez-Pinilla N, Martinez-Zamorano E, Campos-Martin Y, et al.
Paediatric-type nodal follicular lymphoma in a child diagnosed with
chronic myeloid leukaemia. British journal of haematology . Sep
2019;186(6):e207-e209. doi:10.1111/bjh.16089
18. Fabarius A, Kalmanti L, Dietz CT, et al. Impact of unbalanced minor
route versus major route karyotypes at diagnosis on prognosis of CML.Annals of hematology . Dec 2015;94(12):2015-24.
doi:10.1007/s00277-015-2494-9
19. Fabarius A, Giehl M, Frank O, et al. Induction of centrosome and
chromosome aberrations by imatinib in vitro. Leukemia . Sep
2005;19(9):1573-8. doi:10.1038/sj.leu.2403861
20. Pihan GA, Wallace J, Zhou Y, Doxsey SJ. Centrosome abnormalities and
chromosome instability occur together in pre-invasive carcinomas.Cancer research . Mar 15 2003;63(6):1398-404.
21. Duan L, Grunebaum E. Hematological Malignancies Associated With
Primary Immunodeficiency Disorders. Clinical immunology (Orlando,
Fla) . Sep 2018;194:46-59. doi:10.1016/j.clim.2018.06.011
22. Haguet H, Douxfils J, Chatelain C, Graux C, Mullier F, Dogne JM.
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the
Risk of Thrombosis? TH open : companion journal to thrombosis and
haemostasis . Jan 2018;2(1):e68-e88. doi:10.1055/s-0038-1624566
23. Shannon-Lowe C, Rickinson AB, Bell AI. Epstein-Barr virus-associated
lymphomas. Philosophical transactions of the Royal Society of
London Series B, Biological sciences . Oct 19
2017;372(1732)doi:10.1098/rstb.2016.0271
24. Parvaneh N, Filipovich AH, Borkhardt A. Primary immunodeficiencies
predisposed to Epstein-Barr virus-driven haematological diseases.British journal of haematology . Sep 2013;162(5):573-86.
doi:10.1111/bjh.12422
25. Tokuhira M, Watanabe R, Nemoto T, et al. Clinicopathological
analyses in patients with other iatrogenic immunodeficiency-associated
lymphoproliferative diseases and rheumatoid arthritis. Leukemia &
lymphoma . Apr 2012;53(4):616-23. doi:10.3109/10428194.2011.625101
Figure.1 PET/CT images during the diagnosis of the high grade B-cell
lymphoma.
Fused positron emission tomography showing increased fluorodeoxyglucose
uptake at the bilateral cervical and also around the pancreas head and
bilateral inguinal regions.